Some Feedback I got on Earlier Shares - 10/09/25

https://firstwordpharma.com/story/5959626

Is this horse worth backing? 

Is their gene delivery system going to revolutionise treatment, or are other companies working on something better? 

Do you think the big players will licence Nuvec?

1) Biotech is generally risky. Many drugs don't make it to market and this can be after milions-billions spent on research.

This is the con. More than 90% of drug discoveries do not get approved. Only a small percentage of those that do are commercially successful. Apparently, by the time some of them become commercially successful, the patents expire.

2) Those that do make it to market, or which may be bought by a larger pharmecutical company, can make serious money when bought out.

The latter is a pro. There will always be a winner, maybe a few. Being bought out is one way, licensing for royalties is another. Picking the winner from the outset is largely based on luck. 

For example, the phizer biontech collab which happened during the pandemic with mRNA vaccination - rose from 100$ to 400$ peak price in pandemic.

Multiple companies set sail on this drug discovery mission. As you've said, not all of them are a success story. I read, over 100 companies were involved in trying to find a COVID vaccine. I don't know their roles, but the winners were only a handful; Sinopharm, AstraZeneca, Sinovac, Pfizer/BioNTech and Moderna.

Nuvec is in the very early stages of development. Now doing testing on mice. Out an oral alternative with reduced side effects and being a more tageted  therapy would be appealing.

Indeed, N4 is in early stages, which is partly why their share price is in the pennies (that and a bunch of other reasons). Specifically, N4 Pharma specialise in delivery platforms and not drug discovery. I believe they are working towards improving delivery of existing drugs as well a new ones. My take is, they wouldn't be directly responsible for those drugs/therapies, but they will need to prove existing drugs work with their platform. Drug companies would then licence N4's delivery method.

e.g. I bought Synairgen during the pandemic. Biotech company. They have a therapy which is in human trials for asthma  & chronic lung disease. Had a promising trial for covid which may have reduced serverity and duration of disease. Saw stock go from 33p to £2.50.  They're still orking on the drug for copd/asthma and it shows promise and is in human trials. But the shares have just returned to 95p. Still has a viable product which is getting towards licensing stage (so more advanced than nuvec) but share price is awful.

I've read they failed COVID phase 3 trial. This is what tanked the share price. Their inability to secure further funding resulted in them being delisted on the Alternative Investments Market. I couldn't find their stock price in normal places. As mentioned, N4 isn't a drug discovery company. But I do see from this example that late-stage failure can severely affect market price. And this can happen to any company, whether involved in drug discovery or delivery platform. This highlights a risk associated with speculating on winners who've not yet crossed the finish line.

...and that was 4 years ago.

So in summary, you could take a punt. But It is high risk. They're not at human trials yet, which may be a point you may look to invest. But would miss out on that potential stock double to £1. But the odds of them reaching that stage are low.

Agreed, the odds are low. The risk is high. But their slow progress and hinting towards successful early trials might be indicative that they are on the right path. What I think is an important thing about COVID vaccines was the time constraints and an urgency to get products to market. What would normally take years was condensed into months - that's my take. N4 do not appear to be rushing and are steadily achieving what they set out to. Whether it bit they are going about this in the most efficient way possible is not something I'm knowledgeable on.

They also havent published any scientific papers. which is not reassuring.

There is speculation that a possible reason for this is down to IP. Their patents can be reviewed but not any papers for peer review. I suspect they are trying to maintain their edge. 

https://www.investormeetcompany.com/meetings/general-investor-update

Duno if youve watched their invetors call but may be worthwhile.

I'll watch it today

Asseco Poland SA https://share.google/2xJxK9vwnOioRSjKO

Former investment banker friend picked this out. Anticipates true value around 350. But I got in at 190 and it has had a big run recently following a merger/takeover of another tech business. Otherwise im thinking about some gold l; largely a FOMO purchase, but I do think it has further to run.

Some say this stock may be overvalued, and if it is then a correction is imminent. That doesn't mean the business is no good, it just means speculation is over the top. The company's financials would determine it's intrinsic value. Did you analyse the valuation metrics to verify your pals sentiment? It looks good, well the chart does, but cyber security is a real threat. A severe breach could affect the stocks performance. Do your have an exit strategy? Is it a long term hold or a quick get in get out.

Comparable efforts:

Dozens of companies (e.g., Acuitas, Arcturus, CureVac, Precision NanoSystems, Ionis, Moderna) are already developing advanced delivery vectors — lipid, polymer, exosome, viral, and hybrid systems — many years ahead in trials.